Sonata Therapeutics, Inc. , a biotechnology company developing a new class of therapeutics called Network Medicines™, today announced it will be presenting three posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
WATERTOWN, Mass.--(BUSINESS WIRE)--Sonata Therapeutics Inc., a biotechnology company developing a new class of therapeutics called Network Medicines™, today announced it will be presenting three posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Network Medicines are drugs designed to modulate all the key cell types in networks of multifactorial diseases, thereby to halt or potentially reverse damage caused by such diseases. The majority of medicines are designed to disrupt or enhance single pathways in order to stop disease progression, but this approach often requires additional medications that target a different pathway, or combination therapy, to prevent drug resistance or drive response. In contrast, Sonata’s Network Medicines target pathways that change the complete dynamics of multifactorial diseases, resulting in more durable therapeutics and potentially better outcomes for patients.
One of the poster presentations will highlight one of Sonata’s Network Medicines, iART, that reprograms diseased cells to become the coordinators of cure for various indications including cancer. This Network Medicine has demonstrated profound efficacy across a variety of tumor models, representing an exclusive, broadly applicable off-the-shelf therapy for use in oncology.
The second poster presentation will highlight how SNT-20109, one of Sonata’s lead oncology programs, can induce protective immunity and an innovative form of enhanced-immunogenic cell death that has never been characterized in murine cancer models.
The third poster presentation will highlight SNT-4288, another of Sonata’s lead oncology programs, as a novel tool to induce ferroptosis for the treatment of sarcoma.
“As the former President of SITC, I’m thrilled to be back at the organization’s annual meeting as a member of Sonata’s leadership team and showcasing our novel Network Medicines approach that reprograms diseased cells to release curative signals resulting in durable disease resolution,” said Francesco Marincola, M.D., Chief Scientific Officer of Sonata. “I look forward to connecting with my fellow leaders in the field of immuno-oncology and discussing the exciting potential of Sonata’s platform and programs.”
The accepted abstracts are available online through the SITC conference website: https://www.sitcancer.org/2023/abstracts/abstract-titles-publications
In addition, Dr. Marincola will co-chair the symposium “Synthetic Biology – Cell Therapy for Patients with Solid Cancer” on Friday, November 3 from 12:15-1:15 pm PT in Room 11AB of the conference venue. The symposium, sponsored by the Champalimaud Foundation, will highlight real-world challenges, outline solutions and foster collaborations to achieve the ultimate goal of significantly improving the survival of patients with cancer through synthetic biology.
Poster Presentations
Title: Sonata’s Proprietary Intrinsic Antigen Release Technology (iART) Drives In Situ Generation of Potent Anti-Tumor Immunity Across Warm and Cold Tumor Models
Date/Time: Friday, November 3, 2023, 12:00pm-1:30pm and 5:10pm-6:40pm PT
Abstract Number: 1403-B
Location: Ground Level, Exhibit Halls A and B1, San Diego Convention Center
Presenter: Ryan Shaler, Ph.D.
Title: SNT-20109 Induces Protective Immunity in the Murine Syngeneic Tumor Cell Line, CT26: A Dual Approach of Direct Cytotoxicity and Defined Immune Activation
Date/Time: Friday, November 3, 2023, 12:00pm-1:30pm and 5:10pm-6:40pm PT
Abstract Number: 1387
Location: Ground Level, Exhibit Halls A and B1, San Diego Convention Center
Presenter: Ryan Shaler, Ph.D.
Title: Exploring Novel Ferroptosis Inducer as a Promising Strategy for Sarcoma Treatment
Date/Time: Saturday, November 4, 2023, 9:00am-8:30pm PT
Abstract Number: 1442
Location: Ground Level, Exhibit Hall B, San Diego Convention Center
Presenter: Maria Cristina Munteanu, Ph.D.
About Sonata Therapeutics
Sonata Therapeutics is creating a new class of Network Medicines™ designed to modulate all the key cell types in a disease microenvironment required to drive disease resolution. We are building a diverse portfolio of promising medicines for oncology and exploring additional therapeutic areas such as fibrosis and tissue regeneration where multicellular networks play a key role. www.sonatatx.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20231030828275/en/
Source: Sonata Therapeutics, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20231030828275/en
